Next generation immuno-oncology:

Illuminating non-responsive tumours for attack and destruction.


About Grey Wolf

Developing next generation immunotherapies that illuminate non-responsive tumours for destruction by the immune system.

Current immunotherapy approaches target the minority of tumours that are visible to the immune system. By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the neoantigen repertoire in cancer, increasing tumour visibility and extending the therapeutic benefit of immunotherapy to many more cancer patients.

SITC Poster

Request a copy of Grey Wolf's poster presented at the SITC 2019 conference

Get your copy